Projects per year
Fingerprint
Dive into the research topics where Christopher Ryan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 12 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 1 Finished
-
Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy
9/1/11 → 8/31/16
Project: Research project
Research output
-
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Harrison, M. R., Costello, B. A., Bhavsar, N. A., Vaishampayan, U., Pal, S. K., Zakharia, Y., Jim, H. S. L., Fishman, M. N., Molina, A. M., Kyriakopoulos, C. E., Tsao, C. K., Appleman, L. J., Gartrell, B. A., Hussain, A., Stadler, W. M., Agarwal, N., Pachynski, R. K., Hutson, T. E., Hammers, H. J., Ryan, C. W. & 4 others, , 2021, (Accepted/In press) In: Cancer.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
SWOG S1609—A phase 2 basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors: A high-grade neuroendocrine neoplasm cohort
Patel, S. P., Mayerson, E., Chae, Y. K., Strosberg, J., Wang, J., Konda, B., Hayward, J., McLeod, C. M., Chen, H. X., Sharon, E., Othus, M., Ryan, C. W., Plets, M., Blanke, C. D. & Kurzrock, R., 2021, (Accepted/In press) In: Cancer.Research output: Contribution to journal › Article › peer-review
-
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Patel, S. P., Othus, M., Chae, Y. K., Giles, F. J., Hansel, D. E., Singh, P. P., Fontaine, A., Shah, M. H., Kasi, A., Baghdadi, T. A., Matrana, M., Gatalica, Z., Korn, W. M., Hayward, J., McLeod, C., Chen, H. X., Sharon, E., Mayerson, E., Ryan, C. W., Plets, M. & 2 others, , May 15 2020, In: Clinical Cancer Research. 26, 10, p. 2290-2296 7 p.Research output: Contribution to journal › Article › peer-review
Open Access54 Scopus citations -
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J., Ward, J. H., Rushing, D., Okuno, S. H., Reed, D. R., Liebner, D. A., Keedy, V. L., Mascarenhas, L., Davis, L. E., Ryan, C., Reinke, D. K. & Maki, R. G., Nov 1 2020, In: Oncologist. 25, 11, p. e1655-e1662Research output: Contribution to journal › Article › peer-review
Open Access -
Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma
Berlow, N. E., Grasso, C. S., Quist, M. J., Cheng, M., Gandour-Edwards, R., Hernandez, B. S., Michalek, J. E., Ryan, C., Spellman, P., Pal, R., Million, L. S., Renneker, M. & Keller, C., 2020, In: Sarcoma. 2020, 6312480.Research output: Contribution to journal › Article › peer-review
Open Access